Abstract:Introduction: Sphingosine-1-phosphate (S1P) is a potent anti-inflammatory signaling lipid carried in the body by circulating HDL. HDL has been shown to exhibit anti-inflammatory activities through activation of endothelial nitric oxide synthase (eNOS) and subsequent production and release of nitric oxide (NO) by endothelial cells. Objective: The aim of this study is to use synthetic HDL particles to selectively deliver S1P to the site of arterial plaques in order to exert anti-inflammatory activity and modulate the progression of atherosclerosis. Methods/Results: Synthetic HDL (sHDL) particles were prepared using the ApoA1 mimetic peptide 22A (PVLDLFRELLNELLEALKQKLK), dipalmitoylphosphatidylcholine (DPPC) and sphingomyelin. We also prepared sHDL containing either the hydrophobic dye, DiD, or S1P to assess the capability of sHDL to effectively reach atheroma site and induce nitric oxide (NO) release, respectively. The purity of all particles was determined to be > 97% and average particle size was 9.6 ± 0.4 nm for all preparations. To measure sHDL accumulation in the plaque, ApoE -/- mice were intravenously injected with 0.2 mg/kg HDL-DiD. Whole aortas were excised and analysed by IVUS imaging system, revealing significant accumulation of sHDL-DiD in the atherosclerotic lesions. We then tested the ability of sHDL to deliver S1P in vitro and induce NO production by treating human umbilical vein endothelial cells (HUVEC) with 1 mg/mL of 22A-DPPC-sHDL containing 0, 0.05, 0.5, or 5 nmol/mL of S1P using free 22A peptide (1 mg/mL) and saline as controls, and analyzing media by ozone chemiluminescence. Blank sHDL particles increased NO production two-fold over controls (0.27 ± 0.02 μM for 22A-DPPC-sHDLDL, 0.13 ± 0.01 μM PBS and 0.14 ± 0.02 μM for 22A peptide), while HDL-S1P further increased NO release: 0.35 ± 0.03, 0.44 ± 0.01, and 0.59 ± 0.01 μM for HDL with 0.05, 0.5, and 5 nmol/mL S1P, respectively. Conclusions: Our studies show that HDL is capable of delivering hydrophobic cargo to atherosclerotic plaques, making HDL a promising platform to deliver S1P for modulation vascular inflammation and atherosclerosis. In vitro studies have revealed that HDL-S1P is able to increase NO production 2 to 4-fold over saline control setting the basis for future in vivo studies.

Heparin interactions with apoA1 and SAA in inflammation-associated HDL

High-Density Lipoprotein (HDL) Counter-Regulates Serum Amyloid A (Saa)-Induced Spla2-Iie and Spla2-V Expression in Macrophages

Lipid exchange of apolipoprotein A‐I amyloidogenic variants in reconstituted high‐density lipoprotein with artificial membranes

Structural studies of a serum amyloid A octamer that is primed to scaffold lipid nanodiscs

Inhibition of Amyloidosis Using Low-Molecular-Weight Heparins

Apolipoprotein C-Iii In The High-Density Lipoprotein Proteome Of Cerebral Lacunar Infarction Patients Impairs Its Anti-Inflammatory Function

Abstract 335: Atheroma-specific Delivery of Synthetic High-density Lipoprotein Containing Sphingosine-1-phosphate for Modulation of Vascular Inflammation.

High-Density Lipoproteins and Serum Amyloid A (SAA)

The influence of plasma apolipoprotein A-II concentrations on HDL subclass distribution

Unravelling heparin's enhancement of amyloid aggregation in a model peptide system

Vascular Heparan Sulfate and Amyloid-β in Alzheimer's Disease Patients

Characterization of Apolipoprotein A-I Peptide Phospholipid Interaction and Its Effect on HDL Nanodisc Assembly

Expression of Mouse Acute-Phase (saa1.1) and Constitutive (saa4) Serum Amyloid A Isotypes - Influence on Lipoprotein Profiles

Heparan sulfate and heparin interactions with proteins

Apolipoprotein A-II alters the proteome of human lipoproteins and enhances cholesterol efflux from ABCA1

Anti-inflammatory mechanism of Apolipoprotein A-I

Abstract 53: An Abundant Dysfunctional Apolipoprotein A1 in Human Atheroma

Definition of human apolipoprotein A-I epitopes recognized by autoantibodies present in patients with cardiovascular diseases

HDL anti-inflammatory function is impaired and associated with high SAA1 and low APOA4 levels in aneurysmal subarachnoid hemorrhage

HDL Modification by Secretory Phospholipase A2 Promotes Scavenger Receptor Class B Type I Interaction and Accelerates HDL Catabolism

Human Apolipoprotein A-I Exerts a Prophylactic Effect on High-Fat Diet-Induced Atherosclerosis Via Inflammation Inhibition in a Rabbit Model